File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The use of lorcaserin in the management of obesity: A critical appraisal

TitleThe use of lorcaserin in the management of obesity: A critical appraisal
Authors
Keywords5-hydroxytryptamine receptor agonist
Anti-obesity drug
Clinical trial
Obesity
Issue Date2011
PublisherDove Medical Press Ltd. The Journal's web site is located at http://www.dovepress.com/articles.php?issue_id=142
Citation
Drug Design, Development And Therapy, 2011 n. 5, p. 1-7 How to Cite?
AbstractObesity is a chronic disease with a high prevalence in both developed and developing countries. Effective management of this worldwide epidemic will have a significant impact on the health care system globally. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, remain a major component of weight-reduction programs. The development of pharmacotherapy for the management of obesity is still at the infancy stage. Side effects have been the key issue for anti-obesity drugs previously withdrawn from the market. The focus of this review, lorcaserin, is a selective serotonin receptor agonist that is currently undergoing Phase III evaluations. The efficacy of this drug in reducing body weight and improving metabolic parameters of obese patients has been demonstrated in two recent clinical trials. The available evidence indicates that this drug does not show unwanted effects on heart valves or pulmonary artery pressure, and the treatment improves the risk factors for type 2 diabetes and cardiovascular diseases. Despite these promising results, additional experimental and clinical studies are critical for the approval of lorcaserin as a new anti-obesity monodrug therapy by the US Food and Drug Administration. © 2011 Bai and Wang, publisher and licensee Dove Medical Press Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/142455
ISSN
2015 Impact Factor: 2.881
2015 SCImago Journal Rankings: 0.931
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBai, Ben_HK
dc.contributor.authorWang, Yen_HK
dc.date.accessioned2011-10-28T02:46:29Z-
dc.date.available2011-10-28T02:46:29Z-
dc.date.issued2011en_HK
dc.identifier.citationDrug Design, Development And Therapy, 2011 n. 5, p. 1-7en_HK
dc.identifier.issn1177-8881en_HK
dc.identifier.urihttp://hdl.handle.net/10722/142455-
dc.description.abstractObesity is a chronic disease with a high prevalence in both developed and developing countries. Effective management of this worldwide epidemic will have a significant impact on the health care system globally. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, remain a major component of weight-reduction programs. The development of pharmacotherapy for the management of obesity is still at the infancy stage. Side effects have been the key issue for anti-obesity drugs previously withdrawn from the market. The focus of this review, lorcaserin, is a selective serotonin receptor agonist that is currently undergoing Phase III evaluations. The efficacy of this drug in reducing body weight and improving metabolic parameters of obese patients has been demonstrated in two recent clinical trials. The available evidence indicates that this drug does not show unwanted effects on heart valves or pulmonary artery pressure, and the treatment improves the risk factors for type 2 diabetes and cardiovascular diseases. Despite these promising results, additional experimental and clinical studies are critical for the approval of lorcaserin as a new anti-obesity monodrug therapy by the US Food and Drug Administration. © 2011 Bai and Wang, publisher and licensee Dove Medical Press Ltd.en_HK
dc.languageengen_US
dc.publisherDove Medical Press Ltd. The Journal's web site is located at http://www.dovepress.com/articles.php?issue_id=142en_HK
dc.relation.ispartofDrug Design, Development and Therapyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject5-hydroxytryptamine receptor agonisten_HK
dc.subjectAnti-obesity drugen_HK
dc.subjectClinical trialen_HK
dc.subjectObesityen_HK
dc.subject.meshAnti-Obesity Agents - adverse effects - pharmacologyen_US
dc.subject.meshBenzazepines - adverse effects - pharmacologyen_US
dc.subject.meshCardiovascular Diseases - etiology - prevention and controlen_US
dc.subject.meshObesity - complications - drug therapyen_US
dc.subject.meshSerotonin Receptor Agonists - adverse effects - pharmacologyen_US
dc.titleThe use of lorcaserin in the management of obesity: A critical appraisalen_HK
dc.typeArticleen_HK
dc.identifier.emailWang, Y: yuwanghk@hku.hken_HK
dc.identifier.authorityWang, Y=rp00239en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.2147/DDDT.S11945en_HK
dc.identifier.pmid21267355en_US
dc.identifier.pmcidPMC3023275en_US
dc.identifier.scopuseid_2-s2.0-79952960760en_HK
dc.identifier.hkuros184377en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79952960760&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_US
dc.identifier.issue5en_HK
dc.identifier.spage1en_HK
dc.identifier.epage7en_HK
dc.identifier.isiWOS:000208177800001-
dc.publisher.placeNew Zealanden_HK
dc.identifier.scopusauthoridBai, B=37096637200en_HK
dc.identifier.scopusauthoridWang, Y=34973733700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats